Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group.

Manuel Benavides,Javier Gallego Plazas,Carmen Guillen,Ruth Vera,Vega Iranzo,Inmaculada Díaz,Sara Arevalo,A. Pisa,Marta Martin-Richard,Antonieta Salud-Salvia,E. Falcó,A. Sáenz,Jose Luis Manzano,Gema Pulido,Joaquina Martínez-Galán,Roberto A. Pazo Cid,Fernando Rivera,Teresa Garcia,Antonio Irigoyen,Enrique Aranda

Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group.

2014

4122 Background: G and E have shown a survival benefit in the 1st-line setting in mPC. The aim of this study was to assess whether combining C with G+E was safe and effective as compared with G-E i...

Keywords:

Capecitabine
Randomized controlled trial
Metastatic pancreatic cancer
Medicine
Gemcitabine
Erlotinib
Oncology
Internal medicine
survival benefit
first line treatment
collaborative group

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations